Glivec improves overall survival in patients with GIST: Novartis
The results from the trial suggested that at five years 66% of patients taking Glivec for three years remained free of cancer recurrence (primary endpoint) compared to 48%
Vertex Pharmaceuticals and Genomics have agreed a four-year extension to their drug discovery partnership in a deal with a potential value exceeding $220m.